
Mohs Surgery for Melanoma: The 2026 Expert Guide Most Doctors Don’t Give You
Mohs surgery is now NCCN-approved for melanoma in situ and lentigo maligna. Discover who qualifies, real recurrence data, and 2026 cost breakdown.

Mohs surgery is now NCCN-approved for melanoma in situ and lentigo maligna. Discover who qualifies, real recurrence data, and 2026 cost breakdown.

Discover 500+ open melanoma clinical trials in 2026, including mRNA vaccine and CAR-T studies. Step-by-step guide to finding trials and qualifying fast.

Radiation therapy for melanoma uses high-energy beams to destroy cancer cells. Covers 6 types, indications, side effects, and the 2026 immunotherapy combination breakthrough.

BRAF-targeted therapy uses oral precision drugs to block melanoma's mutated BRAF protein. Discover FDA-approved drugs, who qualifies, and how to manage side effects. Updated April 2026.

Learn how immunotherapy works against melanoma, which 5 FDA-approved drugs exist, who qualifies by stage, and what 2026 survival rates actually mean for you.

Wide local excision for melanoma removes the tumor plus a 0.5–2 cm margin. 2026 surgeon-reviewed guide covers procedure steps, recovery timeline, and scar care.

Diagnosed with melanoma in 2026? This complete guide covers every FDA-approved treatment option—surgery, immunotherapy, BRAF therapy, TIL therapy, and the breakthrough mRNA vaccine trial.

Melanoma survival rate ranges from 99% at Stage 0 to 35–52% at Stage 4 with immunotherapy. See the complete 2026 data table, stage-by-stage breakdown, and what it means for you.

Confused by your melanoma blood test results? LDH, ctDNA, S100B, and BRAF biomarkers fully explained with a stage-by-stage guide and 2026 treatment insights.

Everything you need to know about sentinel lymph node biopsy for melanoma — procedure steps, what results mean, recovery timeline, and 2026 treatment options.

From Stage 0 (nearly 100% curable) to Stage 4 (new hope with immunotherapy) — a plain-English, expert-reviewed melanoma staging guide updated for 2026.